Vera Therapeutics
Update in progressVERA (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Vera Therapeutics is a clinical-stage biotechnology company focused on immunological diseases. It develops atacicept, a fully human TACI-Fc fusion protein that blocks BAFF and APRIL, self-administered by subcutaneous injection at home, studied for IgA nephropathy and other autoimmune kidney diseases. It also advances MAU868 for BK viremia (phase 2 completed) and VT-109, a BAFF/APRIL dual-inhibitor BCMA. Formerly Trucode Gene Repair, renamed in 2020; founded 2016; based in Brisbane, California.
Company score
- Sentiment
- 0.54
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.36
- Governance
- 0.10
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.13
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.33
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationUnited States
- CEODr. Marshall W. Fordyce M.D.
- Founded2016
- Employees361
- Websiteveratx.com
Identifiers
- ISINUS92337R1014
- FIGIBBG00Q72WYG3
- CUSIP923351100
- CIK0001831828